Page contentsPage contents Key facts Decision Key facts Active substance cobolimab Therapeutic area Neoplasms benign, malignant and unspecified (incl cysts and polyps) Decision number EMA/PE/0000246904 PIP number EMA/PE/0000246904 Pharmaceutical form(s) Solution for infusion Condition(s) / indication(s) Treatment of all conditions included in the category of malignant neoplasms including lymphoma Route(s) of administration Intravenous use Contact for public enquiries GlaxoSmithKline Trading Services Limited Tel. +1 4388998201E-mail: eu.paediatric-plans@gsk.com Decision type PM: decision on the application for modification of an agreed PIP Decision date 12/09/2025 Compliance check done No Decision EMA/PE/0000246904 : EMA decision of 12 September 2025 on the acceptance of a modification of an agreed paediatric investigation plan for cobolimabAdopted Reference Number: EMADOC-1700519818-2347002 English (EN) (203.56 KB - PDF)First published: 06/11/2025 View Share this page